INT9837

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.11
First Reported 1988
Last Reported 2008
Negated 0
Speculated 0
Reported most in Body
Documents 12
Total Number 14
Disease Relevance 8.41
Pain Relevance 4.55

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

Anatomy Link Frequency
plasma cells 2
pseudotumor 1
mononuclear cell 1
Rf (Mus musculus)
Pain Link Frequency Relevance Heat
spinal inflammation 8 100.00 Very High Very High Very High
cINOD 7 99.90 Very High Very High Very High
imagery 3 99.46 Very High Very High Very High
Etanercept 14 99.16 Very High Very High Very High
rheumatoid arthritis 304 98.92 Very High Very High Very High
methotrexate 17 97.82 Very High Very High Very High
Infliximab 23 96.28 Very High Very High Very High
palliative 1 94.00 High High
dysesthesia 3 93.28 High High
antagonist 3 91.36 High High
Disease Link Frequency Relevance Heat
Fatigue 10 100.00 Very High Very High Very High
Rheumatic Fever 8 100.00 Very High Very High Very High
Low Back Pain 8 100.00 Very High Very High Very High
Rheumatic Heart Disease 8 99.96 Very High Very High Very High
Mental Disorders 35 99.32 Very High Very High Very High
Rheumatoid Arthritis 319 98.92 Very High Very High Very High
Disease 76 98.72 Very High Very High Very High
Dysesthesia 3 93.28 High High
Targeted Disruption 4 90.28 High High
Congenital Anomalies 1 88.48 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Consistent with these results, there was a reduction in RF and ACPA levels after treatment; the reduction in plasma cells was directly related to the decrease in ACPA levels at week 16.
Negative_regulation (reduction) of RF in plasma cells
1) Confidence 0.11 Published 2008 Journal Annals of the Rheumatic Diseases Section Body Doc Link PMC2564787 Disease Relevance 0.20 Pain Relevance 0.07
These data are also in agreement with a previous study showing a trend towards lower synovial immunoglobulin synthesis 2 months after rituximab treatment, although that study was not powered to detect statistically significant changes.5 A role for autoantibodies in RA has been suggested since the discovery of RF in RA and regained interest in the late nineties.20 The previously reported decrease in RF and ACPA levels after rituximab treatment relative to minor changes in total immunoglobulins suggests a role for short-lived plasma cells in their production.2 3 28 This notion is supported by observations in a mouse model; rheumatoid factor transgenic mice were crossed with mice of the autoimmune-prone MRL/lpr strain, after which a spontaneous rheumatoid factor response developed.
Negative_regulation (decrease) of RF in plasma cells associated with targeted disruption, rheumatoid arthritis and sprains and strains
2) Confidence 0.11 Published 2008 Journal Annals of the Rheumatic Diseases Section Body Doc Link PMC2564787 Disease Relevance 0.43 Pain Relevance 0.12
Treatment with prednisone improved clinical symptoms and MRI findings concomitant with reduction of RF titer.
Negative_regulation (reduction) of RF associated with imagery
3) Confidence 0.11 Published 2001 Journal Intern. Med. Section Abstract Doc Link 11579967 Disease Relevance 0.87 Pain Relevance 0.23
There were no significant age related differences for RF physical or mental health related activity limitations and RF lack of energy.


Negative_regulation (lack) of RF associated with mental disorders and fatigue
4) Confidence 0.10 Published 2006 Journal Health Qual Life Outcomes Section Body Doc Link PMC1431510 Disease Relevance 0.78 Pain Relevance 0.23
There was a highly significant decrease in serum levels of IgM-RF at 16 (p?
Negative_regulation (decrease) of RF
5) Confidence 0.08 Published 2008 Journal Annals of the Rheumatic Diseases Section Body Doc Link PMC2564787 Disease Relevance 0 Pain Relevance 0.03
Decreased IgM-RF and ACPA levels after rituximab treatment
Negative_regulation (Decreased) of RF
6) Confidence 0.08 Published 2008 Journal Annals of the Rheumatic Diseases Section Body Doc Link PMC2564787 Disease Relevance 0 Pain Relevance 0.04
Studies are needed on the lines of WHO recommendations for the regional prevalence of RF/RHD in school children throughout the country to detect regional variations.
Negative_regulation (prevalence) of RF associated with rheumatic fever and rheumatic heart disease
7) Confidence 0.05 Published 1995 Journal Indian Heart J Section Abstract Doc Link 8557287 Disease Relevance 1.43 Pain Relevance 0.09
Methotrexate (MTX) at a dose of 5mg/week was started in February 1991 and the pseudotumor decreased in size with a concurrent reduction of ESR, RF and CRP.
Negative_regulation (reduction) of RF in pseudotumor associated with methotrexate
8) Confidence 0.03 Published 1992 Journal Ryumachi Section Abstract Doc Link 1440085 Disease Relevance 0.72 Pain Relevance 0.58
In addition, we also showed that treatment with NSAIDs can decrease RF levels in the synovial space.
Negative_regulation (decrease) of RF associated with cinod
9) Confidence 0.03 Published 1988 Journal Rheumatol. Int. Section Abstract Doc Link 3399796 Disease Relevance 0.39 Pain Relevance 0.44
However, the IgM-RF level in PWM-induced mononuclear cell cultured supernatants of AS was significantly decreased, compared with normal and RA patients.
Negative_regulation (decreased) of RF in mononuclear cell associated with spinal inflammation and rheumatoid arthritis
10) Confidence 0.03 Published 1989 Journal Scand. J. Rheumatol. Section Abstract Doc Link 2523087 Disease Relevance 0.99 Pain Relevance 0.79
Nonetheless, recent studies had reported a significant reduction in the serum titre of rheumatoid factor (RF) and/or anti-cyclic citrullinated peptide antibodies (anti-CCP) during anti-TNFalpha therapy.
Negative_regulation (reduction) of RF
11) Confidence 0.02 Published 2007 Journal Autoimmun Rev Section Abstract Doc Link 17967723 Disease Relevance 1.52 Pain Relevance 0.70
A significant reduction of serum levels of anti-CCP and RF was found in patients who received etanercept combined with DMARDs, compared to patients with DMARDs alone (p = 0.007 and p = 0.006 respectively).
Negative_regulation (reduction) of RF associated with etanercept
12) Confidence 0.01 Published 2007 Journal Biomarker Insights Section Body Doc Link PMC2717818 Disease Relevance 0.27 Pain Relevance 0.39
DMARDs also reduced the anti-CCP or RF level by 25%, but only shorter disease duration (?
Negative_regulation (reduced) of RF associated with disease
13) Confidence 0.01 Published 2007 Journal Biomarker Insights Section Body Doc Link PMC2717818 Disease Relevance 0.50 Pain Relevance 0.34
The results showed a significant reduction of RF from 128 IU/ul (baseline) to 53 IU/ul (78 weeks).
Negative_regulation (reduction) of RF
14) Confidence 0.01 Published 2007 Journal Biomarker Insights Section Body Doc Link PMC2717818 Disease Relevance 0.32 Pain Relevance 0.48

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox